The aim of the study was to evaluate the impact of cholecalciferol supplementation on blood pressure (BP) in patients with arterial hypertension (AH) in the area of Blida (Algeria).

A prospective, cohort, single-center study of 898 individuals with AH (54.1±5.8years) was performed. In addition to antihypertensive therapy every patient was recommended to take cholecalciferol 2000 IU/month. The duration of cholecalciferol supplementation was 3.5±1.7months. The duration of follow-up was 12.4±1.2months. The “dynamics” (d) index was calculated as a difference between values before and after administered therapy.

At baseline office systolic (SBP) and diastolic BP (DBP) averaged at 164/91mmHg. On the follow-up there were their significant (P<0.001) reduction and were 131/82mmHg correspondingly. Target levels of office BP measurements were achieved in 78.1% for SBP and 89.5% for DBP. Serum 25(OH)D total at baseline was 12.4ng/mL, at the end of the follow-up period was 48.4ng/mL (P<0,01). Correlation relationship between dSBP and duration of cholecalciferol intake was established (R=0.47; P=0.02). It was found that intake of diuretics (hydrochlorothiazide at a dose of 12.5mg and higher) as part of combination of antihypertensive therapy influenced the dynamics of serum 25(OH)D (F=4.4; P=0.01) and its level (F=10.9; P=0.01). The highest d25(OH)D was found in the group of patients without diuretics intake. dSBP value was highest (–31.5±19.5) in the group receiving diuretics and cholecalciferol, which was significantly (P<0.001) different from the comparison group. No difference was found for the total amount of antihypertensive medication that was used at 6 and 12 months.

The combined use of cholecalciferol at a dose of 2000 IU/month and diuretic therapy of patients with arterial hypertension allowed to obtain the greatest hypotensive effect on blood pressure.